July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Predicting Long-Term Effects of Ranibizumab Therapy on the Diabetic Retinopathy Severity Score (DRSS) based on the Short-Term DRSS Improvement in the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study
Author Affiliations & Notes
  • Rubbia Afridi
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Muhammad Hassan
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Muhammad Sohail Halim
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Maria Soledad Ormaechea
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Günay Uludağ
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Mohammad Ali Sadiq
    Ophthalmology, University of Louisville, Kentucky, United States
  • Anh Ngoc Tram Tran
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Nam V Nguyen
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Jeong Hun Bae
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Mohamed A Ibrahim
    Ocular Imaging Research and Reading Center (OIRRC), Menlo Park, California, United States
  • Quan Dong Nguyen
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
  • Yasir Jamal Sepah
    Ophthalmology, Byers Eye Institute, Palo Alto, California, United States
    Ocular Imaging Research and Reading Center (OIRRC), Menlo Park, California, United States
  • Footnotes
    Commercial Relationships   Rubbia Afridi, None; Muhammad Hassan, None; Muhammad Sohail Halim, None; Maria Ormaechea, None; Günay Uludağ, None; Mohammad Sadiq, None; Anh Tran, None; Nam Nguyen, None; Jeong Hun Bae, None; Mohamed Ibrahim, Ocular Imaging Research and Reading Center (OIRRC) (E); Quan Nguyen, Genentech (C); Yasir Jamal Sepah, Genentech (C)
  • Footnotes
    Support  NEI P30-EY026877 and Research to Prevent Blindness, Inc
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1730. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rubbia Afridi, Muhammad Hassan, Muhammad Sohail Halim, Maria Soledad Ormaechea, Günay Uludağ, Mohammad Ali Sadiq, Anh Ngoc Tram Tran, Nam V Nguyen, Jeong Hun Bae, Mohamed A Ibrahim, Quan Dong Nguyen, Yasir Jamal Sepah; Predicting Long-Term Effects of Ranibizumab Therapy on the Diabetic Retinopathy Severity Score (DRSS) based on the Short-Term DRSS Improvement in the Ranibizumab for Edema of the Macula in Diabetes – Protocol 3 with High Dose (READ-3) Study. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1730. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the role of degree of short-term improvement in diabetic retinopathy severity score (DRSS) after treatment with Ranibizumab in predicting long term effect on the DRSS in patients with diabetic macular edema (DME).

Methods : In the READ-3 study, patients with DME were stratified into two groups to receive either 0.5mg or 2.0mg monthly intravitreal ranibizumab until month 6, followed by pro-re-nata dosing until month 24. Seven field fundus photographs were evaluated utilizing a 9-step ETDRS DRSS, to assess DR severity at baseline, month 6, and month 24 by a centralized reading center. In the index study, patients from the study groups were combined and sub-divided based on their DRSS score into those with ≥2step (Group 1) improvement and <2 step improvement (Group 2) at month 24. Chi-square and t-test were used to assess the differences between age, gender, race, HbA1c, baseline DRSS, month 6 DRSS, and change in DRSS from baseline to month 6 (Delta M6) among the two groups. Logistic regression was utilized to assess the probability of ≥2step DRSS improvement at month 24 based on the baseline DRSS score and month 6 DRSS response.

Results : Out of 152 eyes (152 patients) randomized in the READ-3 study, 63 eyes (63 patients) fulfilled the inclusion criteria for the index study. Thirty-five eyes with the potential for improvement in the DR severity score were analyzed. Twenty-eight eyes had a prior history of PRP with baseline DR severity score 60. Amongst the 35 eyes, 11 eyes (31.4%) were from group 1 and 24 eyes (68.6%) were from group 2. There was no significant difference between age, gender, race, and HbA1c levels between the two study groups. There was a significant different between the study groups in terms of baseline DRSS, month 6 DRSS, and Delta M6 DRSS. Logistic regression analysis revealed baseline DRSS (p=0.028), month 6 DRSS (p<0.001), and Delta M6 (p<0.001), to be independent predictor of the month 24 DRSS outcomes (p<0.05).

Conclusions : Eyes demonstrating greater than 2-step improvement early in the management of diabetic retinopathy have a greater chance of demonstrating long term improvement in the DRSS score.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×